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Abstract
Our study had three objectives: to extend the plasmid-based transformation protocol to a clinical isolate of C. trachomatis
belonging to the trachoma biovar, to provide ‘‘proof of principle’’ that it is possible to ‘‘knock out’’ selected plasmid genes
(retaining a replication competent plasmid) and to investigate the plasticity of the plasmid. A recently developed, plasmid-
based transformation protocol for LGV isolates of C. trachomatis was modified and a plasmid-free, genital tract C.
trachomatis isolate from Sweden (SWFP-) was genetically transformed. Transformation of this non-LGV C. trachomatis host
required a centrifugation step, but the absence of the natural plasmid removed the need for plaque purification of
transformants. Transformants expressed GFP, were penicillin resistant and iodine stain positive for accumulated glycogen.
The transforming plasmid did not recombine with the host chromosome. A derivative of pGFP::SW2 carrying a deletion of
the plasmid CDS5 gene was engineered. CDS5 encodes pgp3, a protein secreted from the inclusion into the cell cytoplasm.
This plasmid (pCDS5KO) was used to transform C. trachomatis SWFP-, and established that pgp3 is dispensable for plasmid
function. The work shows it is possible to selectively delete segments of the chlamydial plasmid, and this is the first step
towards a detailed molecular dissection of the role of the plasmid. The 3.6 kb b-galactosidase cassette was inserted into the
deletion site of CDS5 to produce plasmid placZ-CDS5KO. Transformants were penicillin resistant, expressed GFP and stained
for glycogen. In addition, they expressed b-galactosidase showing that the lacZ cassette was functional in C. trachomatis. An
assay was developed that allowed the visualisation of individual inclusions by X-gal staining. The ability to express active b-
galactosidase within chlamydial inclusions is an important advance as it allows simple, rapid assays to measure directly
chlamydial infectivity without the need for plaquing, fluorescence or antibody staining.
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Introduction
Members of the Chlamydia are obligate intracellular bacteria of
significant importance in both human and animal pathogenesis.
These microorganisms share a unique developmental cycle, in
which a metabolically active reticulate body (RB) gives rise to
a dense, infectious elementary body (EB) [1]. The process occurs
within a specialised, chlamydia – modified cytoplasmic compart-
ment known as an inclusion.
Chlamydia trachomatis can be divided into two major biological
groups or biovars, those that cause Lymphogranuloma venereum
(LGV biovar) which are highly infectious and cause an invasive
sexually transmitted infection typically involving lymph nodes and
can be spread systemically [2]. By contrast, the vast majority of C.
trachomatis isolates are restricted to the mucosal epithelia of either
the genital tract or the eye and comprise the ‘trachoma biovar’. C.
trachomatis that belong to the trachoma biovar are the major
infectious agents of preventable blindness in the developing world
[3] and also the commonest cause of non-specific urethritis in
developed countries [4]. Sexually transmitted infections caused by
C. trachomatis (trachoma biovar) are frequently undiagnosed in
women, leading to ascending infections that may progress to pelvic
inflammatory disease, salpingitis and consequent infertility [5].
Recently we developed a transformation system for LGV
isolates of C. trachomatis based on using the endogenous chlamydial
plasmid pSW2 to generate a shuttle vector that replicates in both
E. coli and C. trachomatis L2 [6]. The E. coli components of the
shuttle vector were inserted within coding sequence 1 (CDS1) of
the plasmid which had been inactivated by a naturally occurring
deletion. In our previous study all transformations were only
performed using laboratory-adapted LGV isolates that grow
rapidly and have no requirement for centrifugation for cell
infection. In the current study our initial aim was to extend the
‘proof of principle’ of C. trachomatis LGV transformation to
a trachoma biovar isolate that is slower growing and has
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significantly lower infectivity than LGV isolates. It is important
because these plasmid modified trachoma biovariants might also
ultimately be more acceptable as attenuated delivery vehicles for
a live C. trachomatis vaccine.
Nearly all strains of C. trachomatis carry an endogenous 7,500 bp
plasmid; a few plasmid-free clinical isolates have been described
although these are exceedingly rare [7–12]. Studies from plasmid-
cured and naturally occurring plasmid-free C. trachomatis have
shown that the presence of the plasmid is associated with the
ability to accumulate glycogen, TL2 activation and infectivity
[9,13,14]. In vivo studies using a murine model and plasmid
deficient C. muridarum have shown that the plasmid is a virulence
factor [15] although plasmid-free C. caviae do not show reduced
virulence [16]. By contrast, experiments infecting the monkey eye
with a plasmid–cured trachoma isolate of C. trachomatis have
demonstrated that this isolate is avirulent and can also act as
a vaccine [17].
There is thus a great deal of interest in understanding both the
biochemical function and biological role of the plasmid especially
since there are subtle differences between chlamydial species, our
focus is on C. trachomatis [18]. Eight major coding sequences (CDS)
(.100 bases) have been assigned to the chlamydial plasmid [19–
23]. There are four 22-bp tandem repeats located in the intergenic
region between CDS8 and CDS1, together with an upstream AT-
rich region. These features are indicative of an origin of replication
which has been confirmed by electron microscopy [24]. The
positioning of CDS1 and CDS2 downstream of the tandem 22 bp
repeated sequences, coupled with their size and net positive charge
of their predicted products (sharing 32–35% amino acid sequence
identity), indicates that they are replication proteins [25]. The
coding region of CDS1 is a naturally mutable part of the plasmid
and there are numerous examples of this plasmid with premature
stop codons and small deletions within CDS1. The most notable is
the Swedish C. trachomatis new variant which carries a 377 bp
deletion in CDS1 [26,27]. CDS 3 encodes a protein with
homology to DnaB from E. coli, this gene encodes a helicase
enzyme involved in unwinding DNA during replication [21]. The
proteins encoded by CDS 7 and 8 share features in common with
plasmid partition proteins [25]. Thus CDS 2, 3, 7 and 8 are likely
to be essential for plasmid replication.
Specific antibodies, raised to the predicted protein products
encoded by each CDS have been used to investigate the expression
profile for the 8 genes [28]. All 8 encoded proteins are detectable
within the inclusion and their regulation is co-ordinated to the
developmental cycle. Seven of the protein products of the CDSs
are only associated with the inclusion and appeared to specifically
stain EBs or RBs, consistent with a role in plasmid replication.
Unusually, the protein ‘pgp3’ encoded by CDS5 is secreted
beyond the inclusion and into the cell cytoplasm. This strongly
suggests that the role of pgp3 is not related to the regulation of
plasmid functions. Pgp3 assembles into a trimer and is membrane
associated [29]. The mechanism by which this protein reaches the
cell cytosol is unknown although it has been speculated that it
might be an autotransporter rather than secreted through the type
3 mechanism. Antibodies to the assembled trimer of pgp3 are
commonly produced in human chlamydial infection and are
reported to be protective. Exogenous expression of pgp3 in the
cytoplasm of C. trachomatis infected cells does not affect the C.
trachomatis developmental cycle. Whilst there is high overall
conservation (,1% variation) of plasmid DNA sequences within
C. trachomatis [19–22,30], CDS5 appears to be the most variable
region of the plasmid with the highest density of SNPs [27,31].
Taken together these observations strongly suggested that pgp3
does not have a role in plasmid replication or maintenance. Thus
our secondary aim was to test this hypothesis by creating a CDS5
knock out plasmid.
To check for essential function in our CDS5 ‘knock out’ plasmid
vector we needed a C. trachomatis host that was plasmid-free. We
obtained a naturally occurring plasmid-free genital tract C.
trachomatis isolate from Sweden [32]. In this study we confirm that
transformation of this little-passaged, clinical isolate from the
genital tract as a recipient host is possible and that the plasmid
gene encoding pgp3 is dispensable. Finally, we sought to
investigate the plasticity of the chlamydial plasmid as a vector
and to test whether it was possible to replace the gene encoding
pgp3 with an unrelated expression/reporter cassette. For this
purpose we selected the b-galactosidase operon as it has been
extensively used to study gene expression in bacteria [33]. b-
galactosidase is a large inducible multi-subunit enzyme encoded by
a large operon (.3.5 kb) absent from the C. trachomatis genome
[34]. We show that pgp3 can be replaced with this functional
cassette and thus these studies open the way for developing new
improved vectors that will lead to better C. trachomatis assays by
direct staining of inclusions, an important first step in molecular
dissection of plasmid functions.
Materials and Methods
Ethics Statement
All genetic manipulations and containment work was approved
under the UK Health and Safety Executive Genetically Modified
Organisms (contained use) regulations 2000 notification no
GM57,10.1 entitled ‘Genetic transformation of Chlamydiae’.
C. trachomatis Strain SWFP-
C. trachomatis SWFP- (Sweden F strain plasmid minus) is
a plasmid-free serovar F strain isolated in Malmo, Sweden [32].
Two plasmid-free serovar F strains were isolated in 1995 from
a couple (in their 20s) in a stable sexual relationship. The infection
had been acquired abroad by one of them. The C. trachomatis used
in this study was isolated in cell culture from a cervical swab. As
expected, this isolate requires centrifugation to initiate cell
infection and displays the typical C. trachomatis developmental
cycle and compact inclusions in McCoy cells at 48 hrs post
infection.
Propagation of C. trachomatis Strain SWFP-
McCoy cells were used for propagation of C. trachomatis SWFP-
and for the transformation studies. They were grown in
Dulbecco’s modified Eagles’ medium (DMEM) supplemented
with 10% fetal calf serum (FCS). Cells were incubated with C.
trachomatis SWFP- inoculum and centrifuged with a Beckman
Coulter Allegra X-15R Benchtop Centrifuge at 1800 rpm (or
7546g) for 30 min to initiate cell infection. Then the culture
medium was replaced with fresh medium containing cyclohexi-
mide (1 mg/ml) and gentamicin (25 mg/ml). Two days after
infection, the cells were harvested using cell scrapers, and then
spun at 3500 rpm or 28516g for 10 min. The cell pellet was
saved, resuspended in 1 ml of cold 10% PBS, and transferred into
a bijoux tube with glass beads. The cells were lysed by vortexing
for 1 min. The cell debris was removed by spinning at 1000 rpm
or 2336g for 5 min. The supernatant was saved (, 1 ml) and
mixed with an equal volume of phosphate buffer containing 0.4 M
sucrose (4SP), and stored at 280uC.
Purification of Chlamydial EBs and RBs
C. trachomatis EBs and RBs were purified using two cycles of
density gradient centrifugation as previously described [35].
The Chlamydial Plasmid as a Cloning Vector
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Samples harvested from infected cells were overlayed on a 20%
Urografin (Schering Healthcare, UK) in PBS and centrifuged at
100 0006g for 2 h in a Beckman SW28 rotor. The pellet was
collected and resuspended in 2 mL of PBS. The chlamydia were
further purified by overlaying onto a discontinuous urografin
gradient that consisted of 34, 44 and 54% urografin in PBS and
centrifuging at 100 0006g for 2 h in a Beckman SW28 rotor. RBs
banded at the 34%/44% interface and EBs banded at the 44%/
54% interface. The RB and EB bands were collected and were
pelleted by centrifugation at 35 0006g for 30 min in a Beckman
55.2 rotor. The pellets were resuspended in PBS and stored in
aliquots at 280uC.
Recombinant Plasmid Vectors for Transformation
1. Plasmid pGFP::SW2. The construction of pGFP::SW2
was described previously [6]. It contained the pSP73 backbone
with pSW2 (from C. trachomatis SW2) inserted at the unique
BamHI site and a fused gfpcat gene (under the control of a promoter
derived from Neisseria meningitidis) at PstI/SalI sites.
2. Construction of the knockout vector
pCDS5KO. Plasmid pCDS5KO is based on pGFP::SW2. The
only difference is that the 655 bp PacI-BsaBI fragment in
pGFP::SW2 was replaced with a 35 bp oligo 59-TAATAG-
CAAGCTTGAAACTAAAAACCAGGCCTGAT-39, so that the
promoter of CDS5 and L of CDS5 coding region were deleted;
a unique StuI site was included as an additional cloning site.
pCDS5KO was constructed by replacing the 1422 bp EcoRI (in
CDS4) and BsaBI (in CDS5) fragment from pGFP::SW2 with
a 802 bp EcoRI-EcoRV fragment from CDS4 PCR product using
DNA template pGFP::SW2 and primers ORF4_F(RI) (59-
AAAACTGAATTCTTAGAGGCTTATGG-39) and
ORF4_R(RV) (59-AAAAAAGATATCAGGCCTGGTTTT-
TAGTTTCAAGCTTGCTATTA-39). The clone was made by
‘three fragment ligation’: two restriction endonuclease cleavage
fragments from pGFP::SW2 (8101 bp BsaBI fragment and
2016 bp BsaBI-EcoRI fragment) and a 802 bp EcoRI-EcoRV
fragment from the CDS4 PCR product, resulting in a 629 bp
deletion from pGFP::SW2 (between the 24th bp after the stop code
of CDS4 and the BsaBI site on CDS5). The PCR product and
ligations sites, including the intact CDS4 were sequence verified.
The nucleotide sequence and features of pCDS5KO are shown in
Figure S1.
3. Construction of the vector with lacZ (placZ-
CDS5KO). Plasmid placZ-CDS5KO was constructed by clon-
ing a modified lacZ cassette into the unique StuI site in
pCDS5KO. The lacZ cassette contains a ,200 bp promoter from
chlamydiaphage Chp2 ORF5 (Chp2P5) in tandem with the
minimal gpt promoter for lacZ from pSV-B-Gal (Promega). placZ-
CDS5KO was constructed in two steps: firstly, the 226 bp
BamHI-HindIII fragment of Chp2P5 and the 3749 bp HindIII-
SalI fragment of lacZ from pSV-B-Gal (Promega) were cloned into
the BamHI and XhoI sites of pSP73 to get an intermediate
plasmid pSP73-Chp2P5-lacZ. Then the 3855 bp Smal-PsiI
fragment from pSP73-Chp2P5-lacZ (the lacZ cassette) was inserted
into the unique StuI site of pCDS5KO. The nucleotide sequence
and features of placZ-CDS5KO are shown in Figure S2.
Genetic Transformation of C. trachomatis SWFP-
Transformation of C. trachomatis SWFP- was performed using
the Calcium Chloride based transformation protocol developed
for C. trachomatis L2 [6] with the following modifications: (1)
centrifugation (1800 rpm or 7546g for 30 min) to initiate cell
infection; (2) an increased amount of C. trachomatis SWFP- EB for
the initial CaCl2 treatment; (3) selection of transformants in a T25
flask at passage 1. The experimental procedures were as follows:
16108 IFU of SWFP- EBs (concentrated to 10 ml) and 6 mg
plasmid DNA (10 ml) were mixed in a total volume of 250 ml
CaCl2 buffer (10 mM Tris pH 7.4 and 50 mM CaCl2) and then
incubated for 30 min at room temperature. Freshly trypsinised
McCoy cells (76106), resuspended in 250 ml CaCl2 buffer were
then added to the plasmid/EB mix and incubated for a further
20 min at room temperature with occasional mixing. This mixture
was aliquoted to six wells in a six-well plate with 2 mls/well of pre-
warmed DMEM +10% FCS (without cycloheximide or penicillin).
The cells were allowed to settle and incubated at 37uC in 5% CO2
for 1 hour before centrifugation at 1800 rpm or 7546g for
30 min. The plate was returned to the incubator for 2 days.
Infected cells were scraped off from wells with 1 ml filter tip and
bulk harvested (as described earlier) from six wells in 2 ml. This
sample was called T0. The selection of transformants was
performed by infection of McCoy cells in 26T25 flasks using
0.5 ml of T0 (passage 1) and selected with 10 units/ml of penicillin.
Two days after infection, the sample was harvested from 26T25
flasks as ‘T1’. All T1 was used to infect McCoy cells in a T25 flask
with 10 units/ml penicillin. Passaging was continued in T25 flasks
with 10 units/ml of penicillin until normal inclusions were
recovered. The transformants were routinely recovered in passages
2 or 3 (see Figure S3).
Microscopy
Cells in culture and cells infected with C. trachomatis were
routinely visualized by phase contrast microscopy using a Nikon
eclipse TS100 inverted microscope with fluorescence accessories
and a Nikon blue excitation fluorescence filter. Live phase contrast
and fluorescence images were captured using a Nikon DS-Fi1
camera head fitted to the inverted microscope. C. trachomatis
inclusions were stained with iodine as previously described [6].
Counting of inclusion forming units (IFU) to quantify chlamydial
infectivity was performed on serial dilutions of C. trachomatis in
monolayers of McCoy cells grown in 96 well trays. For this assay
inclusions were immunostained as previously described [36].
Time Course of Infection
McCoy cells grown to confluence in 24 well plates were infected
with C. trachomatis at MOI= 1. For C. trachomatis L2(25667R) and
C. trachomatis L2(25667R) transformed with plasmid pGFP::SW2,
EBs were allowed to adsorb to cells for 1 h at 37uC; for C.
trachomatis SWFP- and C. trachomatis SWFP- transformed with
plasmid pGFP::SW2, the 24 well plates were spun at 1800 rpm or
7546g for 30 min at RT. The cells were then overlaid with fresh
culture medium containing cycloheximide (1 mg/ml) and genta-
micin (25 mg/ml), and incubated at 37uC in 5% CO2. The
infection was stopped at 8-hourly time points (8, 16, 24, 32, 40 and
48 h) by scraping up the cells and vortexing with glass beads. The
samples were then rapidly frozen and stored at 280uC and
assayed for infectivity as previously described [6].
Iodine Staining of Inclusions
Iodine staining of inclusions was previously described [6].
Briefly, C. trachomatis strains were cultured in McCoy cells on
coverslips, and infected cells bearing C. trachomatis inclusions were
washed with PBS and then fixed to coverslips with ice-cold
methanol. The coverslips were stained with 5% iodine stain
(containing both potassium iodide and iodine in 50% ethanol) for
10 min. The stain was then changed for 2.5% iodine stain for
10 min and mounted in 5% iodine stain in glycerol (1:1) for
photomicroscopy.
The Chlamydial Plasmid as a Cloning Vector
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Assay for b-galactosidase Expression in C. trachomatis
Inclusions by X-gal Staining
McCoy cells were infected with C. trachomatis transformants
SWFP2/pCDS5KO and SWFP-placZ-CDS5KO in 6-well or 24-
well plates. Two days after infection, the cells were washed with
16PBS and fixed in Formaldehyde fixative (1:10 dilution of 37–
41% Formaldehyde stock in 16PBS) for 15 min. The cells were
washed with 16PBS before adding freshly prepared X-gal staining
solution (1 mg/ml X-gal (from 40 mg/ml x-gal stock in DMSO),
2 mM MgCl2, 5 mM potassium ferrocyanide and 5 mM potas-
sium ferricyanide in 16PBS). The plates were covered with foil
and put in a 37uC incubator overnight.
Southern Blotting
Southern hybridization analysis was previously described [6].
Briefly, the DNA blot was probed with nonradioactive, digox-
igenin-11-dUTP-labeled probes (Random primed DNA labelling)
and chemiluminescence detection with CSPD (Roche Diagnostics
Ltd., Product No. 11 585 614 910). The gfp probe was a 739 bp
Bam HI/Bgl II fragment from pGFP::SW2, which annealed to
a 1445 bp fragment of Bam HI digested pGFP::SW2 or a 3625 bp
fragment of Bgl II digested pGFP::SW2.
Real-time QPCR. Our quantitative real-time PCR protocol
to determine the absolute number of chlamydial plasmids and
genomes in samples using 59- exonuclease (TaqMan) assays with
unlabelled primers and carboxyfluorescein/carboxytetramethylr-
hodamine (FAM/TAMRA) dual-labeled probes has been de-
scribed previously [37]. Real-time PCR cycles were performed in
an ABI PRISM 7700 Sequence Detection System (Applied
Biosystems) according to the manufacturer’s instructions. Reac-
tions were assembled using duplicate standard samples.
Results
Transformation of a Plasmid-free Genital Tract Isolate of
C. trachomatis
Our initial aim was to transform a genital tract isolate of C.
trachomatis; for this purpose we applied the original protocol for
transformation of C. trachomatis L2 to the non-invasive genital tract
(trachoma biovar), plasmid-free Swedish isolate C. trachomatis
SWFP-. However, the infectivity of this plasmid-free isolate
dropped dramatically following the CaCl2 treatment used to make
these bacteria competent. Therefore the protocol was modified by
increasing of the number of EBs and introducing a low speed
centrifugation step which was necessary for efficient cell infection.
By using this modified transformation protocol, transformants of
C. trachomatis SWFP- with pGFP::SW2 were routinely recovered
after 2–3 rounds of penicillin selection (Figure S3). Transformants
of C. trachomatis SWFP- with the vector pGFP::SW2 displayed the
typical C. trachomatis development cycle and compact inclusions
characteristic of genital tract strains in McCoy cells at 48 hrs post
infection (Figure 1A’). Expression of GFP was detected within each
inclusion under blue light (Figure 1B’). Furthermore, inclusions of
C. trachomatis SWFP- transformed with plasmid pGFP::SW2 had
acquired the ability to accumulate glycogen as determined by
iodine staining of inclusions (Figure 1C’).
Mature inclusions of the plasmid-free C. trachomatis SWFP-
isolate have the characteristic ‘bulls-eye’ appearance previously
described for other plasmid-free Chlamydia [14]. In these inclusions,
the Brownian motion or pedesis is confined to the periphery,
leaving a ‘hole-like’ space in the centre. However, transformation
with the vector pGFP::SW2 restored the normal inclusion
phenotype (Figure 1A’). A Southern blot was performed to ensure
that the new phenotypes displayed by C. trachomatis SWFP- were
related to the acquisition of pGFP::SW2 solely as an extrachro-
mosomal element and were not due to its integration with the
bacterial chromosome (potentially disrupting other genes). The
Southern blot showed the presence of pGFP::SWP only as
a supercoiled plasmid (Figure S4).
The pGFP::SW2-transformed C. trachomatis SWFP- appeared to
grow at a faster rate than the untransformed C. trachomatis SWFP-
parent. We also observed a similar, fast growth phenotype between
the pGFP::SW2-transformed plasmid-free LGV isolate C. tracho-
matis L2(25667R) and the untransformed C. trachomatis L2(25667R)
parent. To investigate this observation and place it within
a quantitative framework, one-step growth curves were performed
on the pGFP::SW2 transformed C. trachomatis SWFP- and the
untransformed C. trachomatis SWFP-. These data are shown in
Figure S5 and clearly demonstrate that acquisition of the
transforming plasmid pGFP::SW2 for both C. trachomatis SWFP-
and the plasmid-free LGV isolate C. trachomatis L2(25667R)
increases the infectious yield.
Deletion of CDS5 from the C. trachomatis Plasmid
CDS5 is the most variable of the eight plasmid coding sequences
and its gene product, pgp3, is secreted from the inclusion to the
cell cytoplasm of C. trachomatis infected cells, thus this gene/gene
product is unlikely to be involved in plasmid replication or
maintenance. Hence, the open reading frame and promoter region
for CDS5 were deleted from the shuttle vector pSW2::GFP by
replacing the 655 bp fragment between PacI and BsaBI with
a 35 bp oligonucleotide linker 59-TAATAGCAAGCTTGAAAC-
TAAAAACCAGGCCTGAT-39 (containing a unique StuI site for
use in further cloning); this new plasmid is designated pCDS5KO
(Figure 2, see Materials & Methods for the cloning details).
Plasmid pCDS5KO was maintained in E. coli and then used to
transform C. trachomatis.
Selection of penicillin resistant transformants of C. trachomatis
SWFP- with pCDS5KO was straightforward (Figure S6A) and the
transformed C. trachomatis inclusions fluoresced green (Figure S6B).
In addition, inclusions stained positive for glycogen production
(Figure S6C). These properties were maintained during passage of
the transformants under penicillin selection indicating that the C.
trachomatis SWFP- transformed by pCDS5KO was stable and thus
CDS5 was not required for plasmid replication and maintenance.
Construction of an Expression Cassette
We wanted to investigate whether it was possible to insert
a large, functional gene into the chlamydial plasmid that itself
conferred no selectable advantage on the host bacterium and
could perhaps be useful in developing assays of promoter activity.
Since lactose metabolism was the first system in which gene
regulation was studied there are many genetic tools and assays that
utilise the lactose operon, therefore we choose specifically to study
the b-galactosidase gene/enzyme as proof of principle that such
a construct would be stable and maintained. Furthermore, the C.
trachomatis genome lacks the genes for the metabolism of lactose
thus we could avoid any potential problems of dual functionality or
recombination with the chlamydial chromosomal DNA. The b-
galactosidase enzyme is also a useful test system for functionality as
it is encoded by a large gene (,3.5 kbp) made up of 4
homopolymeric subunits that have to assemble to form the active
enzyme in the bacterial cytoplasm. b-galactosidase hydrolyzes
lactose into glucose and galacatose, which is achieved by
hydrolyzing the beta 1,4 glycosidic linkage between the two
monosaccharides. We chose to use an expression cassette where
a minimal chlamydiaphage promoter was fused in tandem to a b-
galactosidase gene and this was cloned into the deleted CDS5 site
The Chlamydial Plasmid as a Cloning Vector
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of pCDS5KO to generate construct placZ-CDS5KO (Figure 2).
Expression of b-galactosidase in E.coli was demonstrated by
enzyme assay using X-gal in the culture medium as shown in
Figure S7.
Expression of b-galactosidase in C. trachomatis
McCoy cells infected with C. trachomatis SWFP2/pCDS5KO
and C. trachomatis SWFP2/placZ-CDS5KO were grown under
penicillin selection and then fixed and tested for b-galactosidase
activity by X-gal staining. Inclusions formed by C. trachomatis
SWFP2/placZ-CDS5KO stained intensely blue whereas inclu-
sions formed by C. trachomatis SWFP2/pCDS5KO did not stain
(Figure 3). These results demonstrate that the b-galactosidase is
active in C. trachomatis.
Purified EBs and RBs from C. trachomatis transformed by
pCDS5KO were assayed for plasmid copy number and they
showed no significant differences to plasmid copy numbers
compared with the wild type C.trachomatis from previous studies
[27] (Figure S8).
Discussion
A transformation protocol was recently developed for C.
trachomatis L2/434/Bu which is a well-studied, laboratory-adapted
isolate from the LGV biovar that grows rapidly and thus has been
widely used around the world over the past 40 years for laboratory
studies. However, LGV isolates are not typical of most C.
trachomatis and whilst they are a useful model for studying many
aspects of chlamydial cell and molecular microbiology we
Figure 1. Properties of C. trachomatis SWFP2 and C. trachomatis SWFP2 transformed with plasmid pGFP::SW2 (SWFP2/pGFP::SW2). A
to B’: Images of live McCoy cells infected with SWFP2 or SWFP2/pGFP::SW2 under white light (phase contrast, A and A’) and the same fields under
blue light (B and B’). C and C’: Iodine stained McCoy cells (Methanol-fixed on coverslips) infected with SWFP2 (C) and SWFP2/pGFP::SW2 (C’). Mature
SWFP- and SWFP2/pGFP::SW2 inclusions are morphologically distinct by phase contrast microscopy (A and A’). The scale bar represents 20 mm.
doi:10.1371/journal.pone.0059195.g001
The Chlamydial Plasmid as a Cloning Vector
PLOS ONE | www.plosone.org 5 March 2013 | Volume 8 | Issue 3 | e59195
considered that it was important to apply the transformation
technology to C. trachomatis belonging to the trachoma biovar. C.
trachomatis isolates of the trachoma biovar (including genital tract
strains) are generally slower growing than LGV isolates and
require assistance to infect cells, this is usually achieved by
centrifugation or the addition of cations such as DEAE cellulose.
Preparations of the trachoma biovar isolates have much lower
particle to infectivity ratios [38], perhaps an indication of their
reduced virulence in vivo. For this project we have applied the
plasmid transformation protocol to a Swedish genital tract isolate
of C. trachomatis that has had little adaptation to cell culture. In our
previous work selecting transformants with the LGV C. trachomatis
isolate L2/434/Bu a key element of the experimental design was
the need to perform multiple rounds of plaque purification to
obtain clonal transformants. LGV isolates of C. trachomatis form
large and easily reproducible plaques, by contrast plaquing of the
less invasive, non-LGV C. trachomatis is a technically demanding
and time consuming procedure. During the plaque purification
process the endogenous chlamydial plasmid was eliminated from
the C. trachomatis L2/434/Bu host, presumably by competition and
incompatibility with the transforming vector under antibiotic
selection. The Swedish C. trachomatis isolate (SWFP-) was selected
Figure 2. Construction of the CDS5 knock-out vector and insertion of the lacZ cassette. A. The regions between plasmid CDS4-CDS6 are
shown, which highlight differences between the three plasmid constructs listed. In pCDS5KO, the ,600 bp PacI-BsaBI fragment in pGFP::SW2 was
replaced with a 35 bp oligo (including a unique StuI site for further cloning), resulting the deletion of CDS5. In placZ-CDS5KO, a lacZ cassette was
inserted into the StuI site of pCDS5KO. This lacZ cassette contains a ,200 bp promoter from chlamydiaphage Chp2 ORF5 (Chp2P5) placed in front of
a 3.6 kb HindIII-PsiI lacZ fragment from pSV-B-Gal (Promega). The drawings are not to scale. B. Map showing the features of plasmid pCDS5KO. The
inner circle represents the plasmid pSW2 from C. trachomatis SW2 (black) and the non-chlamydial sequences (red). The circle is graduated with 1 kb
scale bars. The location of CDS 4 and CDS 6 are marked and the deletion of CDS5 is represented by the scissors symbol.
doi:10.1371/journal.pone.0059195.g002
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as a potential recipient host as it is a naturally occurring plasmid-
free strain and thus our experimental design, incorporating this
isolate, meant plaque purification was not required. In this work
we have demonstrated that the Calcium Chloride- based trans-
formation protocol works with a genital tract isolate that has had
very limited attenuation under laboratory conditions. Using the
original plasmid vector pGFP::SW2 we have routinely and rapidly
recovered transformants of C. trachomatis SWFP- with the modified
protocol. These results showed that the use of a genital tract isolate
as a recipient host, with the introduction of a centrifugation step
into the standard transformation protocol, allowed the selection of
transformants. Acquisition of the recombinant plasmid restores
glycogen biosynthesis (a function associated with the plasmid in C.
trachomatis) (Figure 1C’), and the transformants are penicillin
resistant and express the green fluorescent protein (Figure 1B’).
The additional advantage of using plasmid-free C. trachomatis as
a recipient host is that it speeds up the process removing the need
for plaque purification and eliminates the possibility of the
transforming vector recombining with the endogenous plasmid.
We noticed that the pGFP::SW2 transformants grew faster than
the untransformed recipient C.trachomatis (SWFP-), consistent with
the evidence that the C. trachomatis plasmid is a virulence factor
[39]. Previously we had also transformed a naturally occurring
plasmid-free LGV isolate of C. trachomatis and this also appeared to
grow more quickly once transformed by the plasmid pGFP::SW2.
Thus plasmid-free C. trachomatis transformed with the recombinant
plasmid, which brings a replicative burden, have an increased
growth rate and infectious yield. It has been suggested that
Figure 3. Properties of C. trachomatis SWFP2 transformed with plasmid pCDS5KO and placZ-CDS5KO. Microscopic images of live McCoy
cells infected with C. trachomatis SWFP2 transformed by pCDS5KO (A) and placZ CDS5KO (B) under white light (phase contrast) and the same fields
under blue light (C and D). Panels E and F show McCoy cells infected with C. trachomatis SWFP- transformed by pCDS5KO (E) and placZ-CDS5KO (F).
The cells in these panels have been fixed with Formaldehyde and stained with X-gal. Active b-galactosidase cleaves X-gal to form an insoluble blue
precipitate. Mature SWFP2/pCDS5KO and SWFP2/placZ CDS5KO inclusions are morphologically indistinguishable by phase contrast microscopy (A
and B). The scale bar represents 20 mm.
doi:10.1371/journal.pone.0059195.g003
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plasmid-free C. trachomatis might be useful as an attenuated vaccine
because of its reduced virulence. Our in vitro data showing a more
rapid growth characteristics provide supportive evidence that the
plasmid has a role in C. trachomatis virulence. However, some
caution may need to be exercised in such an approach to
vaccination. The original clinical data from Sweden show the
plasmid-free Swedish isolate retained its ability to infect in vivo as
two plasmid-free ‘serovar F’ isolates were obtained, one from each
adult in the couple, indicating that transmission of the plasmid-free
C. trachomatis had occurred between partners. Also, as mixed
infections occur, plasmids could be transferred back into plasmid
deficient C. trachomatis isolates, restoring virulence.
To construct the original shuttle vector we had inserted E. coli
components (origin of replication and selectable markers) within
CDS1 as this region of the chlamydial plasmid is naturally
mutable, hinting that the function of CDS1 was not essential. In
the current study we wanted to investigate whether other regions
of the chlamydial plasmid were dispensable and could be used for
further insertion of ‘foreign’ DNA. For this purpose we chose
CDS5 since the gene product, the protein pgp3, is secreted to the
infected cell cytoplasm and forms a complex trimeric structure.
Since this protein appears to have no role within EBs or RBs we
considered that it was unlikely to be involved in plasmid
maintenance or replication. We constructed a simple deletion
mutant of CDS5 in the shuttle vector pSW2::GFP and trans-
formation of the genital tract C. trachomatis SWFP- with this new
construct pCDS5KO was possible proving that CDS5 is not an
essential component of the plasmid, required for replication or
maintenance. Plasmid free isolates of Chlamydia have two clear
phenotypes, those with the inability to accumulate glycogen which
demonstrate the production of ‘bull’s eye’ inclusions. The parental
C. trachomatis SWFP- also exhibited both of these phenotypic traits.
Recently we proved that acquisition of the chlamydial plasmid by
an LGV, plasmid-free isolate restored both the ability to
accumulate glycogen and to produce ‘normal’ inclusions and this
was also the case for C. trachomatis SWFP- when transformed with
the standard transformation vector pSW2::GFP. C. trachomatis
SWFP- transformed with the pCDS5KO plasmid had restored
both the ability to accumulate glycogen and normal inclusion
morphology indicating that neither of these properties were related
to the presence of CDS5. To verify that CDS5 has no role in
plasmid maintenance and stability, the copy number of the CDS5
knockout and the starting vector were measured for both EBs and
RBs, and found to be similar to that of wild-type genital tract
isolates of C. trachomatis [27] indicating that CDS5 or its gene
product pgp3 has no role in regulating plasmid copy number. To
test whether the deleted region of the plasmid in CDS5 was
a suitable cloning/insertion site for foreign DNA and to explore
the possible size limit of a stable and functional insert we
constructed a plasmid cassette based on pCDS5KO containing the
lac Z gene. Transformation of C. trachomatis with this new plasmid,
placZ-CDS5KO, showed that b-galactosidase was expressed as an
active enzyme.
Thus, in conclusion, we have shown that it is possible to
transform a genital tract isolate of C. trachomatis (that requires
centrifugation to initiate cell infection). Acquisition of the plasmid
increases the growth rate and thereby shortens the developmental
cycle. However, in contrast to studies on C. muridarum where
infectivity is significantly reduced in plasmid- cured isolates,
plasmid bearing C. trachomatis still require centrifugation to assist
infection. It is possible to engineer a knockout for the CDS5 and
insert foreign DNA at this site in the plasmid. As proof of principle
we have shown that it is possible to express functional b-
galactosidase. Knock out of the CDS5 region has no effect on the
plasmid-associated phenotypes of glycogen accumulation and the
production of bull’s eye inclusions. The ability to express active b-
galactosidase within chlamydial inclusions is an important advance
as it opens the possibility to measure accurately promoter activity
and to devise assays to assess effectors of promoter activity during
the developmental cycle. This work has established that it is
possible to selectively delete segments of the chlamydial plasmid;
this is the first step towards a detailed molecular dissection of the
role of the plasmid in regulating biochemical functions (e.g
glycogen accumulation), biological functions (inclusion morphol-
ogy) and virulence. The next steps in this work are to evaluate the
effects of this gene knock out on infection in vivo.
Supporting Information
Figure S1 Plasmid pCDS5KO nucleotide sequence and
features. The pCDS5KO plasmid is a derivative of pGFP::SW2
and has the C. trachomatis plasmid CDS5 region deleted.
(DOC)
Figure S2 Plasmid placZ-CDS5KO nucleotide sequence
and features. This plasmid has the lacZ gene under control of
a tandem arrangement of the chlamydiaphage (Chp2) ORF5
promoter and a minimal E. coli gpt promoter.
(DOC)
Figure S3 Microscopic images showing the early stages
of recovery for transformants of C. trachomatis SWFP-
with plasmid pGFP::SW2. The transformation mix (C.
trachomatis SWFP-, plasmid DNA and McCoy cells in CaCl2/Tris
buffer) was seeded onto 6-well plate in penicillin-free medium for
two days before harvest T0 (A). Recovery of transformants was
performed by 2–3 rounds of passages under penicillin selection (10
units/ml) in McCoy cells in T25 flasks (B–F). After two days in
Passage 1, all inclusions appeared to be ‘abnormal’ (B). Neverthe-
less, after two days in Passage 2, ‘normal’ inclusions begin to
emerge (C&D, D is the same field as C under blue light). More
transformants were grown in Passage 3 (E&F, F is the same filed as
E under blue light). Scale bars: 40 mm in images A&B and 100 mm
in C–F.
(TIF)
Figure S4 Southern blot of C. trachomatis SWFP- (2p)
and C. trachomatis SWFP- transformed by plasmid
pGFP::SW2 (+p) using a DIG-labelled GFP probe. Six
chlamydial genomic DNA samples (,0.5 mg DNA/lane) were
loaded on 1% agarose gel in pairs together with HyperLadder I
(5 ml) from BIOLINE (Cat No. BIO-33025). The agarose gel
image was taken before DNA transfer (A). The DNA blot was
hybridized with the GFP probe (B). The Bam HI digestion of
pGFP::SW2 generated 3 fragments: 7169 bp, 2925 bp and
1445 bp (containing GFP probe sequence). The Bgl II digestion
of pGFP::SW2 generated 4 fragments: 5555 bp, 3625 bp (contain-
ing the GFP probe sequence), 1693 bp and 666 bp. The Southern
blot showed that the hybridization signals at expected positions in
all SWFP2/pGFP::SW2 samples (uncut or digested); whilst no
hybridization signal was detected in all SWFP- samples (uncut or
digested) (B).
(TIF)
Figure S5 C. trachomatis SWFP- and C. trachomatis L2
(25667R) grow faster and give a higher yield when
transformed by pGFP::SW2. (A) C. trachomatis SWFP- (black)
and C. trachomatis SWFP- transformed with pGFP::SW2 (green) (B)
C. trachomatis L2 (25667R) and C. trachomatis L2 (25667R)
transformed with pGFP::SW2. McCoy cells in a 24 well tissue
culture tray grown to confluence were infected with C. trachomatis
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at MOI=1 and were cultured as described. The yield of C.
trachomatis (IFU) per culture or single well is shown on the y – axis
and time of sampling post infection is shown on the x –axis. The
experiments were repeated in quadruplicate and standard error
bars are shown for each sample point.
(TIF)
Figure S6 Properties of C. trachomatis SWFP- trans-
formed with plasmid pCDS5KO (SWFP2/pCDS5KO).
(A) Image of live McCoy cells infected with SWFP2/pCDS5KO
under white light (phase contrast). (B) The same field as (A) under
blue light. (C) Iodine stained McCoy cells (Methanol-fixed on
coverslips) infected with SWFP2/pCDS5KO. The transformant
SWFP2/pCDS5KO expressed the green fluorescent protein and
was iodine-stain positive. Scale bar represents 20 mm.
(TIF)
Figure S7 Phenotypic properties E. coli transformed
with plasmids pCDS5KO and placZ-CDS5KO. E. coli strain
MC1061 transformed with pCDS5KO and placZ-CDS5KO was
grown on (A) an LB-amp agar plate, and (B) LB-Xgal-amp agar
plate. Expression of the green fluorescent protein was visualised
under blue light.
(TIF)
Figure S8 Plasmid copy number in C. trachomatis
SWFP- transformed by pCDS5KO. Genomic DNA was
extracted from gradient-purified EBs and RBs and analysed by
qPCR to determine the plasmid/genome ratios (P/G). Standard
error bars are shown.
(TIF)
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